戻る Agendas
Session 0102 Future Direction of Global Drug Development With ICH E17 Guideline Focusing on MRCTs
Session Chair(s)
Yoshiaki Uyama, PHD, MS, RPH
Associate Executive Director
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Speaker(s)
Impacts of E17 Guideline for Drug Review and Approval in Taiwan
Lih-Jiuan Hsu
Center for Drug Evaluation, Taiwan, Taiwan
Deputy Executive Director
Global Drug Development Impact of ICH E17 Guideline_An Industry Perspective
Patrick Brady, PHARMD
IQVIA, United States
Global Head, Therapeutic Innovation & Regulatory Science